Poor glycemic control impairs recovery from central retinal vein occlusion.

Central macular thickness was significantly higher in the poor glycemic control group compared to the good glycemic control group at 3 months.

• Poor glycemic control group CMT: 367.0 ± 43.3 µm vs. good glycemic control group: 288.2 ± 36.6 µm at 3 months
• Difference was statistically significant (p = 0.016)
• Poor glycemic control was defined as HbA1c >42 mmol/mol; good glycemic control as HbA1c ≤42 mmol/mol
• HbA1c was measured within 6 months before or at diagnosis

Central macular thickness remained significantly higher in the poor glycemic control group compared to the good glycemic control group at 1 year.

• Poor glycemic control group CMT: 380.8 ± 44.8 µm vs. good glycemic control group: 302.0 ± 71.3 µm at 1 year
• Difference was statistically significant (p = 0.035)
• The poor glycemic control group showed persistent or worsening macular thickness over the follow-up period

HbA1c levels correlated with central macular thickness at 3 months but not significantly at 1 year.

• At 3 months, HbA1c correlated with CMT with R² = 0.514, p = 0.045
• At 1 year, the correlation did not reach statistical significance (R² = 0.246, p = 0.071)
• The correlation was stronger at 3 months than at 1 year

The study enrolled 40 adult patients with central retinal vein occlusion, of whom 10 had suboptimal glycemic control.

• This was a retrospective cohort study conducted at Helsinki University Hospital, Finland
• Patients had HbA1c levels measured within 6 months before or at diagnosis of CRVO
• 10 out of 40 patients (25%) were in the poor glycemic control group (HbA1c >42 mmol/mol)
• Assessment time points were baseline, 3 months, and 1 year